Results 51 to 60 of about 22,935 (284)

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

The place of gliclazide MB in modern treatment strategies for patients with type 2 diabetes mellitus

Сахарный диабет
Sulfonylurea (SU) are an effective class of oral hypoglycemic drugs that have been used in clinical practice for more than 70 years. Despite the common mechanism of action, members of the class have significant intraclass differences in hypoglycemic ...
N. A. Petunina, N. S. Martirosian, E. V. Goncharova, M. E. Telnova, I. A. Kuzina, A. O. Shchetinina, E. A. Elmurzaeva   +6 more
doaj   +1 more source

Diabetes and bone. Focus on DPP-4 inhibitors

Медицинский совет, 2015
Pathology of bone homeostasis in diabetes mellitus (DM) is a significant problem that must be considered when selecting anti-diabetic therapy. Many anti-diabetic drugs have a specific effect on bone homeostasis which should be taken into account when ...
A. Y. Babenko, V. S. Nikitin, T. L. Karonova   +2 more
doaj   +1 more source

Effects of thiazolidinediones and sulfonylureas in patients with diabetes

, 2010
In the current literature there are different opinions about the use of thiazolidinediones or sulfonylureas. Some authors have reported that thiazolidinediones increase total body glucose disposal and reduce hepatic glucose production, reducing both ...
DEROSA, GIUSEPPE, MAFFIOLI, PAMELA
core   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Seletividade do nicosulfuron em três estádios fenológicos de milho-pipoca Selectivity of nicosulfuron at three popcorn growth stages

Planta Daninha, 2012
Objetivou-se com este trabalho avaliar a seletividade do herbicida nicosulfuron em três estádios fenológicos de milho-pipoca (híbrido White A 448).
S.D. Cavalieri, F.M.L. Silva, E.D. Velini, A.R. São José, S.M. Ulloa, A. Datta, J.D. Cavalieri, S.Z Knezevic   +7 more
doaj   +1 more source

Misunderstandings and controversies about the insulin-secreting properties of antidiabetic sulfonylureas.

, 2017
After 60 years of use in the treatment of type 2 diabetes, hypoglycemic sulfonylureas remain a recommended option in current therapeutic charts. Their binding to sulfonylurea receptor-1, the regulatory subunit of ATP-sensitive potassium channels in the ...
Henquin, Jean-Claude, Jean-Claude Henquin   +1 more
core   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

A new mesangial triumvirate: Sulfonylureas, their receptors and endosulfines

, 2002
Although sulfonylureas have long been therapeutically utilized for their hypoglycemic properties in type 2 diabetic patients, there is a paucity of clinical or experimental data that suggests that this pharmacotherapeutic class confers a benefit on the ...
Szamosfalvi, Balázs, Yee, Jerry
core   +1 more source

Response of maize (Zea mays L.) to rimsulfuron under salt conditions

Acta Societatis Botanicorum Poloniae, 2011
Investigations were carried out to determine the possible interaction between salinity (60 mmol*dm-3 NaCl) and phytotoxicity of herbicide Titus 25 DF (sulfonylurea herbicide containing active ingredient rimsulfuron).
Elżbieta Sacała, Anna Demczuk, Tomasz Michalski   +2 more
doaj   +1 more source